Our finding of an increase in CECs in SO/ER or BV/ER, but not monotherapy erlotinib-treated patients is consistent with our earlier finding of a similar increase in renal cell cancer patients treated with the VEGFR–TKI sunitinib (Vroling et al, 2009). Here, KDR is linked to renal cell adenocarcinoma.